An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
Abstract
Article AbstractObjective: To examine the efficacy and tolerability of a new injectable formulation of olanzapine, olanzapine long-acting injection (LAI), relative to placebo for treatment of acutely ill patients with schizophrenia.Method: Patients with DSM-IV or DSM-IV-TR schizophrenia in this 8-week, double-blind study were randomly assigned to receive 210 mg/2 weeks, 300 mg/2 weeks, or 405 mg/4 weeks of olanzapine LAI or placebo/2 weeks. No oral antipsychotic supplementation was permitted. The primary efficacy measure was mean baseline-to-end point change in Positive and Negative Syndrome Scale (PANSS) total score. The study was conducted from June 2004 to April 2005. Results: Mean baseline-to-end point decreases in PANSS total scores were significantly greater for all olanzapine LAI regimens relative to placebo (all p values < .001). The 300 mg/2 weeks and 405 mg/4 weeks olanzapine LAI groups separated from placebo on the PANSS total at 3 days after starting treatment, and all olanzapine LAI groups separated from placebo by 7 days. Rates of clinical improvement (end point Clinical Global Impressions-Improvement scale score <= 3) were significantly higher for all olanzapine LAI groups relative to placebo (p < .001). Incidences of sedation and increased appetite were significantly higher for 300 mg/2 weeks olanzapine LAI relative to placebo (p < .05). Mean weight gain (3.2-4.8 vs. 0.3 kg, p = 7% of baseline (23.6-35.4% vs. 12.4%, p <= .046) were significantly greater for olanzapine LAI relative to placebo. Significant differences between all olanzapine LAI groups and placebo were observed regarding mean baseline-to-end point changes in fasting total cholesterol (5.5-10.4 vs. -7.0 mg/dL; p <= .015) and between the 210 mg/2 weeks and 405 mg/4 weeks groups (26.3-30.3 vs. -9.4 mg/dL; p <= .016), but not the 300 mg/2 weeks group (17.6 mg/dL; p = .055), and placebo for fasting triglycerides. Conclusions: In this 8-week study, olanzapine LAI administered at 2- or 4-week injection intervals was significantly more efficacious than placebo for the treatment of acutely ill patients with schizophrenia despite no use of supplemental oral antipsychotics. Consistent with changes previously observed with oral olanzapine, clinically significant weight gain and changes in some lipid parameters were observed in patients treated with olanzapine LAI.Trial Registration:clinicaltrials.gov Identifier: NCT00088478
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Only one trial of olanzapine LAI was available (Lauriello et al., 2008).
“only one trial was available (Lauriello et al., 2008)”
From Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis (2024) · cites this paper as Lauriello et al., 2008
Cited by
Sorted by citations
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490 · see citing works
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 418 · see citing works
“No other concomitant oral antipsychotic treatment was permitted (Lauriello et al. 2008).”
BackgroundDose-response meta-analysis of antipsychotic drugs for acute schizophrenia
Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010034 · Cited by 301 · see citing works
Placebo Response in Antipsychotic Clinical Trials
Rutherford, B. R., Pott, E., Tandler, J. M., Wall, M. M., Roose, S. P., & Lieberman, J. A. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1319 · Cited by 152 · see citing works
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
Wu, H., Siafis, S., Hamza, T., Schneider‐Thoma, J., Davis, J. M., Salanti, G., & Leucht, S. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac001 · Cited by 131 · see citing works
Detke, H. C., McDonnell, D., Brunner, E., Zhao, F., Sorsaburu, S., Stefaniak, V. J., & Corya, S. A. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-43 · Cited by 118 · see citing works
Self-citationPsychopharmacology and adverse effects of antipsychotic long-acting injections: A review
Taylor, D. M. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s13 · Cited by 117 · see citing works
Mallikaarjun, S., Kane, J. M., Bricmont, P., McQuade, R. D., Carson, W. H., Sanchez, R., Forbes, R. A., & Fleischhacker, W. W. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.06.041 · Cited by 108 · see citing works
Gopal, S., Vijapurkar, U., Lim, P., Ma, M., Eerdekens, M., & Hough, D. W. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110372817 · Cited by 103 · see citing works
“The efficacy of LAI atypical antipsychotics in the acute treatment of schizophrenia has been shown in short-term trials (Chue et al., 2005; Kane et al., 2003; Keks et al., 2007; Lauriello et al., 2008; Lindenmayer et al., 2004).”
BackgroundBarriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
Parellada, E., & Bioque, M. (2016) · CNS Drugs · doi:10.1007/s40263-016-0350-7 · Cited by 89 · see citing works
New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
Citrome, L. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811984 · Cited by 81 · see citing works
“Lauriello et al. (2008) Short-term study 404 8 Acute 210 mg/2 weeks, 405 mg/4 weeks or 300 mg/2 weeks All three doses of OLAI were superior to placebo in improving the PANSS total score [64] Kane et al. (2010) Longer-term study 1065 Varies, up to 24 weeks Stable Same dose of oral olanzapine (10, 15…”
BackgroundAgid, O., Foussias, G., & Remington, G. J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.499125 · Cited by 79 · see citing works
“A recent 8-week, randomized, double-blind study in 404 acutely ill patients with schizophrenia demonstrated significant antipsychotic efficacy with olanzapine-LAI versus placebo [99].”
BackgroundSabé, M., Zhao, N., Crippa, A., & Kaiser, S. (2021) · Schizophrenia · doi:10.1038/s41537-021-00171-2 · Cited by 74 · see citing works
Long-acting injectable antipsychotics: focus on olanzapine pamoate
Lindenmayer, J. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3072 · Cited by 68 · see citing works
“Efficacy and safety studies Acute treatment One large, double-blind, placebo controlled, 8-week study of olanzapine LAI in 404 inpatients with acute schizophrenia patients compared 210 mg every 2 weeks, 300 mg every 2 weeks, 405 mg every 4 weeks and placebo in a 1:1:1:1 randomized design.(5) All three olanzapine doses…”
MethodSecond-generation antipsychotic long-acting injections: Systematic review
Fleischhacker, W. W. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s29 · Cited by 68 · see citing works
Heres, S., Reichhart, T., Hamann, J., Mendel, R., Leucht, S., & Kissling, W. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2009.12.020 · Cited by 64 · see citing works
“With additional SGA depots becoming available [23], this current critical limitation may lose relevance step by step.”
BackgroundEffect of Antipsychotic Medications on Glucose and Lipid Levels
Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010368678 · Cited by 65 · see citing works
“A number of studies measured blood glucose levels following antipsychotic therapy but found no significant changes with therapy.(11,12,19-22) None of these studies excluded prior antipsychotic use or measured insulin to assess insulin resistance.”
BackgroundRauch, A.-S., & Fleischhacker, W. W. (2013) · CNS Drugs · doi:10.1007/s40263-013-0083-9 · Cited by 64 · see citing works
Olanzapine pamoate: a stick in time?
Citrome, L. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01900.x · Cited by 63 · see citing works
Olanzapine: review of safety 2008
Kantrowitz, J. T., & Citrome, L. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802423234 · Cited by 62 · see citing works
Bushe, C., Falk, D. M., Anand, E., Casillas, M., Perrin, E., Chhabra-Khanna, R., & Detke, H. C. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0450-9 · Cited by 55 · see citing works
“In both the post-marketing safety studies and spontaneous reports, the symptoms of PDSS were consistent with those observed in clinical trials and those associated with an oral olanzapine overdose [4,5].”
BackgroundResultAlphs, L. D., Bossie, C. A., Sliwa, J. K., Ma, Y.-W., & Turner, N. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-12 · Cited by 55 · see citing works
“antipsychotics, including oral agents [2,3,11,13,28-30].”
BackgroundFuriak, N. M., Ascher‐Svanum, H., Klein, R. W., Smolen, L. J., Lawson, A. H., Montgomery, W. S., & Conley, R. R. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.554533 · Cited by 51 · see citing works
Milz, R., Benson, C. J., Knight, K., Antunes, J., Najarian, D. M., Rengel, P. M. L., Wang, S., Richarz, U., Gopal, S., & Kane, J. M. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s395383 · Cited by 47 · see citing works
Wang, D., Schneider-Thoma, J., Siafis, S., Qin, M., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.03.003 · Cited by 44 · see citing works
“Olanzapine LAI came out as the most efficacious antipsychotic in several outcomes, but it must be noted that only one trial was available (Lauriello et al., 2008) and that therefore its confidence intervals were usually large.”
BackgroundLuedecke, D., Schöttle, D., Karow, A., Lambert, M., & Naber, D. (2014) · CNS Drugs · doi:10.1007/s40263-014-0216-9 · Cited by 40 · see citing works
Gentile, S. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1313 · Cited by 40 · see citing works
“This formulation is suspended in aqueous vehicle for deep gluteal intramuscular injection.(13) Its pharmacokinetics enable therapeutic levels to be available after the first injection, with concentrations increasing with subsequent injection until a steady state is achieved after approximately 3 months.”
BackgroundMethodResultInfluentialOlanzapine Long-Acting Injection
Frampton, J. E. (2010) · Drugs · doi:10.2165/11204930-000000000-00000 · Cited by 40 · see citing works
“[46] In most instances (80%[46]), the initial signs and symptoms of post-injection syndrome have developed within 1 hour following administration of OLAI; post-injection syndrome events appearing 1–3 and >3 hours after injection have been rare (<1/1000 injections) and very rare (<1/10000 injections), respectively.”
BackgroundInfluentialLong-acting injectable antipsychotics: what, when, and how
Citrome, L. (2021) · CNS Spectrums · doi:10.1017/s1092852921000249 · Cited by 41 · see citing works
Keith, S. J. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.1.9 · Cited by 36 · see citing works
Bitter, I., Katona, L., Zámbori, J., Takács, P., Fehér, L., Diels, J., Bacskai, M., Láng, Z., Gyáni, G., & Czobor, P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.02.003 · Cited by 34 · see citing works
“Oral formulations of second generation antipsychotic drugs (SGA) have been introduced in the last two decades and recently they were followed by long-acting formulations (Kane et al., 2003; Lauriello et al., 2008).”
McDonnell, D., Kryzhanovskaya, L. A., Zhao, F., Detke, H. C., & Feldman, P. D. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1225 · Cited by 35 · see citing works
“Primary reports on its tolerability and efficacy have previously been made (Kane et al., 2010; Lauriello et al., 2008).”
BackgroundSelf-citationComparison of Olanzapine Long-Acting Injection and Oral Olanzapine
Detke, H. C., Weiden, P. J., Llorca, P., Choukour, M., Watson, S. B., Brunner, E., & Ascher‐Svanum, H. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000140 · Cited by 34 · see citing works
Stip, É., Abdel‐Baki, A., Bloom, D., Grignon, S., & Roy, M. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600608 · Cited by 33 · see citing works
Mitchell, M., Kothare, P., Bergstrom, R., Zhao, F., Jen, K. Y., Walker, D., Johnson, J., & McDonnell, D. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.023 · Cited by 31 · see citing works
“The clinical and PK data generated formed the basis for the selection of several Phase III dose regimens that were further evaluated in 2 double-blind, randomized trials for treatment of patients with schizophrenia.(14,15) Olanzapine LAI is approved in the United States, Europe, and several countries in other regions,…”
BackgroundMethodSelf-citationMcDonnell, D., Landry, J., & Detke, H. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000038 · Cited by 30 · see citing works
“The safety and tolerability profile of olanzapine LAI was similar to that of oral olanzapine, except for the adverse events (AEs) related to the injection (Lauriello et al., 2008; Kane et al., 2010).”
BackgroundMethodInfluentialSelf-citationLorenzo, R. D. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5463 · Cited by 30 · see citing works
“In order to conform to FDA requirements, the parent pharmaceutical company conducted 2 studies: a short-term, placebo-controlled study 48 and a long-term, controlled trial.”
Cañas, F., & Möller, H. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.506712 · Cited by 30 · see citing works
“6% of patients treated with OP, with all reactions mild-moderate in severity and none resulting in treatment discontinuation [61].”
BackgroundInfluentialKoola, M. M., Wehring, H. J., & Kelly, D. L. (2012) · Journal of Dual Diagnosis · doi:10.1080/15504263.2012.647345 · Cited by 30 · see citing works
“There was no statistically significant difference between the three dosage groups (Lauriello et al., 2008).”
BackgroundPharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden
Einarson, T. R., Vicente, C., Zilbershtein, R., Piwko, C., Bø, C. N., Pudas, H., Jensen, R., & Hemels, M. E. H. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2013.852243 · Cited by 28 · see citing works
Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review
Berardis, D. D., Marini, S., Carano, A., Lang, A., Cavuto, M., Piersanti, M., Fornaro, M., Perna, G., Valchera, A., Mazza, M., et al. (2013) · Current Clinical Pharmacology · doi:10.2174/15748847113089990056 · Cited by 27 · see citing works
Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia
Olivares, J. M., Pinal, B., & Cinos, C. (2011) · Neuropsychiatry · doi:10.2217/npy.11.24 · Cited by 26 · see citing works
Long-Acting Injectable Antipsychotics: An Underutilized Treatment Option
Heres, S. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14com09541 · Cited by 25 · see citing works
Ascher‐Svanum, H., Zhao, F., Detke, H. C., Nyhuis, A. W., Lawson, A. H., Stauffer, V. L., Montgomery, W. S., Witte, M. M., & McDonnell, D. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-152 · Cited by 24 · see citing works
“[11] Patients were male or female, aged 18 to 75 years, with a diagnosis of schizophrenia (DSM-IV or DSM-IV-TR), and a PANSS-derived Brief Psychiatric Rating Scale (BPRS, 0-6 scale) score ≥30, reflecting a moderate-to-high level of illness severity.”
MethodSelf-citationCitrome, L. (2009) · Patient Preference and Adherence · doi:10.2147/ppa.s5734 · Cited by 24 · see citing works
Einarson, T. R., Pudas, H., Goswami, P., Impe, K. V., & Bereza, B. G. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1100115 · Cited by 24 · see citing works
Meyers, K. J., Upadhyaya, H. P., Landry, J., Chhabra-Khanna, R., Falk, D. M., Rao, B. S., & Jones, M. (2017) · BJPsych Open · doi:10.1192/bjpo.bp.116.004382 · Cited by 25 · see citing works
A review of olanzapine pamoate
Chue, P. S., & Chue, J. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.686169 · Cited by 24 · see citing works
“In the first double-blind (DB) 8-week study, acutely ill patients with schizophrenia (n = 404) were randomized (1:1:1:1) to OLAI at doses of 300 mg/2 weeks, 405 mg/4 weeks, 210 mg/2 weeks or placebo (PBO) injection [30].”
BackgroundMethodTowards a framework for treatment effectiveness in schizophrenia
Juckel, G., de Bartolomeis, A., Gorwood, P. A. P. M., Mosolov, S. N., Pani, L., Rossi, A., & Sanjuán, J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s61672 · Cited by 23 · see citing works
Hill, A. L., Sun, B., Karagianis, J. L., Watson, S. B., & McDonnell, D. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-28 · Cited by 24 · see citing works
“Background Olanzapine long-acting injection (LAI) has been studied in both the short-term [1] and long-term [2] treatment of schizophrenia.”
BackgroundSelf-citationBaruch, N., Das, M., Sharda, A., et al. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314531982 · Cited by 23 · see citing works
“Olanzapine pamoate is one of a few atypical antipsychotics available as a depot preparation and is not associated with a high risk of extrapyramidal side effects [Lauriello et al. 2008; Bishara and Taylor, 2008].”
BackgroundGentile, S. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12824 · Cited by 23 · see citing works
“A third group of patients was randomized to oral OLA.”
InfluentialRobinson, D. G., Suett, M., Wilhelm, A., Chaijale, N., Franzenburg, K. R., Gandhi, S. K., Cloud, B., & Mychaskiw, M. A. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02455-8 · Cited by 22 · see citing works
“Long-acting injectable antipsychotic therapies (LAIs) provide alternative dosing schedules from once every 2 weeks up to once every 6 months [9–11].”
Atkins, S., Detke, H. C., McDonnell, D., Case, M. G., & Wang, S. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-7 · Cited by 21 · see citing works
“Discussion The safety and efficacy of olanzapine LAI have been reported previously and have been shown to be similar to those of oral olanzapine [10-12], with the exception being the occurrence of injection-related AEs.”
BackgroundMethodResultInfluentialSelf-citationLong-Acting Injectable Aripiprazole
Gopalakrishna, G., Aggarwal, A., & Lauriello, J. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.goag.043013 · Cited by 20 · see citing works
Self-citationWitte, M. M., Case, M. G., Schuh, K. J., & Ascher‐Svanum, H. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.657300 · Cited by 20 · see citing works
Taipale, H., Tanskanen, A., Luykx, J., Solmi, M., Leucht, S., Correll, C., & Tiihonen, J. (2022) · Schizophrenia bulletin · doi:10.1093/schbul/sbac039 · Cited by 18 · see citing works
“Moreover, the only randomized controlled dose-finding study of olanzapine LAI also suggested that at the highest dose examined, 300 mg biweekly, a plateau of the dose-response curve had not been reached yet.(6,24) However, the superior effectiveness of olanzapine LAI for relapse prevention must be balanced with the we…”
BackgroundOlanzapine pamoate for the treatment of schizophrenia
Naber, D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.553193 · Cited by 17 · see citing works
“1 Acute treatment In a double-blind, placebo-controlled, 8-week study of olanzapine pamoate, 404 inpatients with acute schizophrenia were treated with 210 mg every 2 weeks, 300 mg every 2 weeks, 405 mg every 4 weeks or placebo in a 1:1:1:1 randomized design [22].”
BackgroundMethodInfluentialEinarson, T. R., Vicente, C., Zilbershtein, R., Piwko, C., Bø, C. N., Pudas, H., & Hemels, M. E. H. (2012) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2012.00670.x · Cited by 17 · see citing works
“(23), 67% were dosed every 2 weeks as were 47% of those in the longer trial by Kane et al.”
MethodAntipsychotic Drugs and Dysregulated Glucose Homeostasis
Smith, E. C. C., Agarwal, S. M., Panganiban, K. J., Maksyutynska, K., Monteiro, J., Lee, J., Prasad, F., Ji, A., Shah, D., Cavalier, S., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2240 · Cited by 18 · see citing works
Einarson, T. R., Pudas, H., Zilbershtein, R., Jensen, R., Vicente, C., Piwko, C., & Hemels, M. E. H. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.823869 · Cited by 16 · see citing works
“) 300 mg every 2 weeks 3 doses (as per Zypadhera Product Monograph(16)), then 473 mg every 4 weeks maintenance (Lauriello et al.(37))”
BackgroundMethodKasinathan, J. G., Sharp, G. D., & Barker, A. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316656319 · Cited by 16 · see citing works
McDonnell, D., Andersen, S. W., Detke, H. C., Zhao, F., & Watson, S. B. (2011) · Clinical Medicine Insights Psychiatry · doi:10.4137/cmpsy.s6659 · Cited by 15 · see citing works
Self-citationIntegrated treatment of schizophrenia
Altamura, A. C., Fagiolini, A. M., Galderisi, S., Rocca, P., & Rossi, A. (2015) · Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" · Cited by 15 · see citing works
Spidel, A. L., Greaves, C., Yuille, J., & Lecomte, T. (2015) · International Journal of Law and Psychiatry · doi:10.1016/j.ijlp.2015.01.026 · Cited by 14 · see citing works
“Researchers have suggested that patients with more severe symptoms may not experience significant improvement in their symptoms despite pharmacological treatment (Lauriello et al., 2008).”
BackgroundAscher‐Svanum, H., Peng, X., Montgomery, W. S., Faries, D. E., Lawson, A. H., Witte, M. M., Novick, D., Jemiai, N., Perrin, E., & McDonnell, D. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.03.015 · Cited by 14 · see citing works
“The efficacy, safety, and tolerability of olanzapine-LAI have been demonstrated in several studies, including two randomized double-blind trials, one comparing olanzapine-LAI with placebo [16] and the other with oral olanzapine [6].”
BackgroundSelf-citationKisely, S., Sawyer, E., Robinson, G., & Siskind, D. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.028 · Cited by 17 · see citing works
“Three studies had less than 10% loss at follow-up (Chouinard et al., 1982; Lauriello et al., 2008; Kane et al., 2010; Witte et al., 2012).”
BackgroundAscher‐Svanum, H., Novick, D., Haro, J. M., Bertsch, J., McDonnell, D., & Detke, H. C. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-224 · Cited by 13 · see citing works
“The long-acting formulation of olanzapine is available for the treatment of patients with schizophrenia and its safety and efficacy have been shown previously [21,22].”
BackgroundSelf-citationDelivery Systems and Dosing for Antipsychotics
Rabin, C. R., & Siegel, S. J. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_11 · Cited by 14 · see citing works
Anand, E., Berggren, L., Deix, C., Tóth, Á., & McDonnell, D. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s79347 · Cited by 13 · see citing works
Self-citationBrugnoli, R., Rapinesi, C., Kotzalidis, G. D., et al. (2016) · Rivista di psichiatria · doi:10.1708/2246.24194 · Cited by 13 · see citing works
Einarson, T. R., Zilbershtein, R., Skoupá, J., Veselá, Š., Garg, M., & Hemels, M. E. H. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.820193 · Cited by 13 · see citing works
“OLZ-LAI Treatment initiation for relapse requiring hospitalization 300 mg every 2 weeks 3, then 473 mg every 4 weeks Zypadhera product summary(16), Lauriello et al.(31) Relapse not requiring hospitalization 473 mg every 4 weeks Lauriello et al.”
BackgroundMethodDetke, H. C., Zhao, F., & Witte, M. M. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-51 · Cited by 12 · see citing works
“Three of the studies compared the respective formulation of olanzapine (LAI or oral) with placebo [9,14,16]; two of the studies employed a non-therapeutic reference dose of oral olanzapine (1 mg/day) [15,16].”
BackgroundResultInfluentialWehring, H. J., Thedford, S., Koola, M. M., & Kelly, D. L. (2011) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s4091 · Cited by 11 · see citing works
Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia
Jukić, V., Jakovljević, M., Filipčić, I., Herceg, M., Silić, A., Tomljanović, T., Zilbershtein, R., Jensen, R., Hemels, M. E. H., & Einarson, T. R. (2013) · Value in Health Regional Issues · doi:10.1016/j.vhri.2013.06.008 · Cited by 12 · see citing works
“Table 1 lists the clinical inputs used in this mode, by drug, as well as the sources of information [22,28–30,34–53].”
BackgroundAscher‐Svanum, H., Montgomery, B., McDonnell, D., Coleman, & Feldman, P. D. (2012) · International Journal of General Medicine · doi:10.2147/ijgm.s29052 · Cited by 10 · see citing works
Self-citationGentile, S. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0004 · Cited by 11 · see citing works
“The main safety results of two trials [9], [32] were previously described [6].”
ResultThe quality of reporting of phase II and III trials for new antipsychotics: a systematic review
Patel, M. X., Collins, S., Hellier, J. M., Bhatia, G., & Murray, R. M. (2014) · Psychological Medicine · doi:10.1017/s0033291714001214 · Cited by 9 · see citing works
Olanzapine pamoate for the treatment of schizophrenia – a safety evaluation
Samalin, L., Garay, R. P., Ameg, A., & Llorca, P. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1141893 · Cited by 9 · see citing works
New advances in pharmacotherapy for early psychosis
Emsley, R. A. (2009) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2009.00124.x · Cited by 9 · see citing works
“Long-acting olanzapine injection has also proven effective in the management of established disease.(33) Of these two formulations, only RLAI has been evaluated specifically within the setting of early psychosis.”
BackgroundDrug safety evaluation of olanzapine pamoate
Schöttle, D., Kuhnigk, O., & Naber, D. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.832753 · Cited by 8 · see citing works
“In the acute study [26], no significant differences between the olanzapine pamoate groups and placebo could be demonstrated regarding motor side effects and use of anticholinergics (placebo 8.”
BackgroundMethodInfluentialJones, M., Andrews, J. S., Faries, D. E., Landry, J., Xu, J., Detke, H. C., Chhabra-Khanna, R., & McDonnell, D. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0669-5 · Cited by 8 · see citing works
“Olanzapine LAI has been shown to be efficacious for the treatment of schizophrenia in both actively psychotic [19] and stable patients [20].”
Self-citationHaro, J. M., Ascher‐Svanum, H., Novick, D., et al. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s61409 · Cited by 8 · see citing works
“16 Although there is evidence supporting the effectiveness of olanzapine-LAI 17,18 and the associated short-term improvements in patient functioning and quality of life, 12 little is known about long-term changes in the level of functioning in schizophrenia patients receiving maintenance therapy…”
Self-citationHill, A. L., Sun, B., & McDonnell, D. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.hisu.020813 · Cited by 8 · see citing works
Self-citationPostinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection
Venkatesan, V., Khanra, S., Mandal, K., & Deepak, M. B. (2019) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000329 · Cited by 8 · see citing works
“Olanzapine long-acting (OLAI) depot injection of pamoate salt of olanzapine is one among few other available long-acting antipsychotic depot injections that have been found to be effective for treatment of schizophrenia in both acute and maintenance phases of the illness.(6,7) It is administered via a deep intramuscul…”
BackgroundDisease Management: Multidimensional Approaches to Incomplete Recovery in Psychosis
Lambert, T. J. R. (2010) · Advances in biological psychiatry · doi:10.1159/000319811 · Cited by 8 · see citing works
Self-citationSchizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 8 · see citing works
Postinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection
Sarangula, S. M., Mythri, S. V., Sanjay, Y., & Reddy, M. S. S. (2016) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.185946 · Cited by 6 · see citing works
“It is proven to be effective in patients with schizophrenia in both acute and stable phases.[6,7] The efficacy and side effect profile of olanzapine pamoate are similar to the oral olanzapine except for the risk of injection site reaction and postinjection delirium/sedation syndrome (PDSS).”
BackgroundChoosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide
Citrome, L. (2025) · CNS Spectrums · doi:10.1017/s1092852925100400 · Cited by 5 · see citing works
Ting, E., Kamalvand, S., Shang, D., Siskind, D. J., & Kisely, S. R. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.12.004 · Cited by 6 · see citing works
Meyer, R., Skov, K., Dhillon, I. K., Olsson, E., Graudal, N. A., Baandrup, L., & Jűrgens, G. (2022) · Biomedicines · doi:10.3390/biomedicines11010082 · Cited by 5 · see citing works
“, studies with more than one follow-up time point, were used for sensitivity analyses: sublingual asenapine n = 2 [25,26], oral olanzapine n = 9 [33,37,40–46], LAI olanzapine n = 1 [50], oral quetiapine n = 5 [51–55], ER oral quetiapine n = 1 [59], and oral zotepine n = 2 [60,61].”
BackgroundMethodInfluentialDetke, H. C., Lauriello, J., Landry, J., et al. (2014) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1443 · Cited by 3 · see citing works
“Previous studies have established the efficacy and safety of olanzapine LAI in patients with schizophrenia treated for up to eight weeks of acute therapy (Lauriello et al., 2008) or for up to 24 weeks of maintenance therapy (Kane et al.”
MethodResultInfluentialSelf-citationCase, M. G., Karagianis, J. L., Schuh, K. J., et al. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.835715 · Cited by 3 · see citing works
[Olanzapine long-acting post-injection syndrome: a case report and brief review].
Duran‐Sindreu, S., Grasa, E., Corripio-Collado, I., Sauras-Quetcuti, R. B., Keymer-Gausset, A., Roldán, A., Alonso-Solís, A., Figueras-Vilalta, M., & Álvarez, E. (2013) · PubMed · Cited by 3 · see citing works
Prevention of Catatonia With Olanzapine Long-Acting Injectable
Ifteni, P.-I., & Teodorescu, A. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000479 · Cited by 3 · see citing works
“The pamoate salt of olanzapine is one of the secondgeneration antipsychotic depot formulations whose efficacy and safety in the treatment of schizophrenia has been previously documented.(4,5) The common recommendation is to avoid antipsychotics, at least during the early phases of catatonia treatment, to avoid antipsy…”
BackgroundChartier, F., Rouillon, F., Berggren, L., Jamonneau, I., Falissard, B., & Llorca, P. (2017) · L Encéphale · doi:10.1016/j.encep.2017.05.004 · Cited by 3 · see citing works
Management of Medication-Related Adverse Effects
Atsariyasing, W., & Goldman, M. B. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0656-7_12 · Cited by 2 · see citing works
Almost all antipsychotics result in weight gain: A meta-analysis
Bak, M. (2016) · Journal of Obesity & Weight loss Therapy · doi:10.4172/2165-7904.c1.039 · Cited by 2 · see citing works
Grover, S., Singla, H., Chakrabarti, S., & Avasthi, A. (2019) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_269_19 · Cited by 2 · see citing works
“This finding supports the available efficacy data of olanzapine LAI in patients with schizophrenia[27,28] and occasional case reports which have reported a beneficial effect of olanzapine LAI in patients with TRS.”
ResultComment évaluer l’efficacité d’un antipsychotique d’action prolongée au moyen d’un essai clinique ?
Fakra, É., Azorin, J. M., Belzeaux-R, R., et al. (2016) · L Encéphale · doi:10.1016/s0013-7006(17)30053-2 · Cited by 2 · see citing works
- Authors
- Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C. C., & McDonnell, D.
- Affiliations
- University of New Mexico (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-05-15
- Volume
- 69
- Issue
- 5
- Pages
- 790-799
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2076607047
- Cited by
- 120
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 3 · 2019: 5 · 2018: 3 · 2017: 3 · 2016: 10 · 2015: 7 · 2014: 14 · 2013: 18 · 2012: 9
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, acute schizophrenia, antipsychotic efficacy, tolerability, PANSS, sedation, weight gain, hypertriglyceridemia, adverse effects, injectable antipsychotics, dose comparison, relapse prevention
- MeSH terms
- Olanzapine, Acute Disease, Adolescent, Adult, Aged, Benzodiazepines, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Schizophrenia, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
